Metastatic Triple-Negative Breast Cancer Clinical Trial
Official title:
Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile
Recent progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies including breast cancer. It has been shown that levels of certain cytokines were correlated with increased response to immunotherapy in patients with metastatic breast cancer. In this study investigators will perform cytokine profiling among patients diagnosed with metastatic triple-negative breast cancer at different time points during the treatment.
This is a prospective study that has two groups of patients as determined by their prescribed treatment plan. Group A (control group) are patients with metastatic triple-negative breast cancer (TNBC) who receive chemotherapy only (current standard of care). Group B (experimental group) are patients with mTNBC who receive a combination of chemotherapy and IT immunotherapy (Atezolizumab) which is a standard of care for patients whose tumor express >1% of PD-L1 molecules. T-cell cytokines will be measures prior to treatment and at multiple time points during the treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04986852 -
Olinvacimab With Pembrolizumab in Patients With mTNBC
|
Phase 2 | |
| Recruiting |
NCT05831553 -
TIP in Patients Affected by Metastatic TNBC
|
||
| Recruiting |
NCT05570253 -
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04454437 -
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
|
Phase 2 | |
| Recruiting |
NCT05101096 -
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05227664 -
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
| Completed |
NCT03004183 -
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
|
Phase 2 | |
| Recruiting |
NCT06027268 -
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05746728 -
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05089643 -
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
|
Phase 2 |